ADALAT CC Drug Patent Profile
✉ Email this page to a colleague
When do Adalat Cc patents expire, and what generic alternatives are available?
Adalat Cc is a drug marketed by Norwich and is included in one NDA.
The generic ingredient in ADALAT CC is nifedipine. There are thirty-nine drug master file entries for this compound. Thirty-eight suppliers are listed for this compound. Additional details are available on the nifedipine profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Adalat Cc
A generic version of ADALAT CC was approved as nifedipine by ACTAVIS ELIZABETH on January 8th, 1991.
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for ADALAT CC?
- What are the global sales for ADALAT CC?
- What is Average Wholesale Price for ADALAT CC?
Summary for ADALAT CC
| US Patents: | 0 |
| Applicants: | 1 |
| NDAs: | 1 |
| Raw Ingredient (Bulk) Api Vendors: | 165 |
| Clinical Trials: | 29 |
| Patent Applications: | 1,183 |
| Drug Prices: | Drug price information for ADALAT CC |
| What excipients (inactive ingredients) are in ADALAT CC? | ADALAT CC excipients list |
| DailyMed Link: | ADALAT CC at DailyMed |
Recent Clinical Trials for ADALAT CC
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| Cao Yu | Phase 1 |
| Jing Liu | Phase 4 |
| Lehigh Valley Hospital | Phase 4 |
US Patents and Regulatory Information for ADALAT CC
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Norwich | ADALAT CC | nifedipine | TABLET, EXTENDED RELEASE;ORAL | 020198-001 | Apr 21, 1993 | DISCN | Yes | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| Norwich | ADALAT CC | nifedipine | TABLET, EXTENDED RELEASE;ORAL | 020198-002 | Apr 21, 1993 | DISCN | Yes | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| Norwich | ADALAT CC | nifedipine | TABLET, EXTENDED RELEASE;ORAL | 020198-003 | Apr 21, 1993 | DISCN | Yes | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for ADALAT CC
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Norwich | ADALAT CC | nifedipine | TABLET, EXTENDED RELEASE;ORAL | 020198-001 | Apr 21, 1993 | ⤷ Sign Up | ⤷ Sign Up |
| Norwich | ADALAT CC | nifedipine | TABLET, EXTENDED RELEASE;ORAL | 020198-002 | Apr 21, 1993 | ⤷ Sign Up | ⤷ Sign Up |
| Norwich | ADALAT CC | nifedipine | TABLET, EXTENDED RELEASE;ORAL | 020198-003 | Apr 21, 1993 | ⤷ Sign Up | ⤷ Sign Up |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
International Patents for ADALAT CC
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Major Patent Expirations 2024 - 2025
NCE-1 Patent Challenge Dates 2024 - 2025
Trigger-based marketing for the life sciences
Get DrugPatentWatch Business Intelligence Reports at Amazon.com
DrugChatter - AI-based answers to questions about drugs
RxJam - Digital Marketing for Life Sciences
Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2024, www.DrugPatentWatch.com.
See Primary Research Papers Citing DrugPatentWatch
Follow DrugPatentWatch:
